Loading stock data…
Penumbra (PEN)
$318.73+0.83 (+0.26%)
Market ClosedLast close Jul 24
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Penumbra, Inc. in the Healthcare sector is trading at $318.73 with a market capitalization of $12.5B. Wall Street consensus targets $361.58 (12 analysts), implying a +13.4% move over the next 12 months. The stock is currently 12% below its 52-week high of $362.41, remaining 1.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $374.76M↓ | $385.38M↑ | $354.69M↑ | $339.45M↑ | $324.14M |
| Gross Profit | $253.41M↓ | $262.13M↑ | $240.42M↑ | $224.01M↑ | $215.88M |
| Operating Income | $38.23M↓ | $59.23M↑ | $48.84M↑ | $40.83M↑ | $40.35M |
| Net Income | $32.58M↓ | $47.34M↑ | $45.85M↑ | $45.27M↑ | $39.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.61%
Volume
Today's trading volume
300,590
Recent News
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study
Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy results for THUNDERBOLT in stroke care. A leading stroke center has begun using THUNDERBOLT in clinical practice, expanding its real world footprint. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, including stroke. The FDA clearance...
3 Medical Device Stocks Giving Investors a Different Healthcare Play
Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.
IQV vs. PEN: Which Stock Is the Better Value Option?
IQV vs. PEN: Which Stock Is the Better Value Option?
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
GMED vs. PEN: Which Stock Is the Better Value Option?
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.